Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2010

View Archived Issues

MerLion Pharmaceuticals claims new macrolides

Astellas reports last year's product highlights

GE Healthcare identifies novel contrast agents for X-ray-based diagnosis

Novel antiviral compounds disclosed by GlaxoSmithKline

ACADIA describes new muscarinic acetylcholine receptor agonists

Merck & Co. identifies novel PDE10A inhibitors

Promising data reported on house dust mite allergy therapies

Zolpidem improves limb dystonia

Pridopidine beneficial in patients with Huntington's disease

ExonHit and Genmab sign agreement on new potential breast cancer targets

AMRI completes acquisition of Hyaluron

MultiCell contracts CDSS to manage phase IIb MCT-125 trial

GPR17 antagonist ticagrelor shows preclinical promise to treat demyelinating conditions

Endocyte presents interim phase I data on FR-targeting conjugates in solid tumors

Idarubicin/busulphan improves outcome of autograft in patients with NPM1-mutant AML

SCH-900105 is safe and advances from phase I to phase II trial

Promega and CDI validate predictive stem cell-based cardiotoxicity assays

FoldRx achieves funds to market tafamidis meglumine

Anacor reports on phase IIb trial of AN-2728 in psoriasis

Galera to advance dismutase mimetics for prevention of oral mucositis

EC grants QPI-1002 orphan status for prevention of DGF

Biogen enrolls first patient in phase II combination trial of BG-12 in MS

Pieris begins phase I trial of anticalin PRS-050 in cancer

Inovio begins immunization in phase I trial of VGX-3400X universal flu vaccine

EMA approves update to bortezomib label for multiple myeloma

Tranzyme and Norgine to codevelop ulimorelin in Europe and other regions

Anacor's AN-3365 achieves proof of concept in collaboration with GSK

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...